Synergism of theophylline and anticholinergics to inhibit haloperidol-induced catalepsy: A potential treatment for extrapyramidal syndromes

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 34, Issue 8, 2010, Pages 1465-1471

  González Lugo, Olga E ^a   Ceballos Huerta, Fátima ^a   Jiménez Capdeville, María E ^a   Arankowsky Sandoval, Gloria ^b   Góngora Alfaro, José L ^b  

^a UNIVERSIDAD AUTÓNOMA DE SAN LUIS POTOSÍ   (Mexico)

^b UNIVERSIDAD AUTÓNOMA DE YUCATÁN   (Mexico)

Author keywords

Acute dystonia; Methylxanthines; Parkinsonism; Schizophrenia; Tardive dyskinesia

Indexed keywords

8 CYCLOPENTYL 1,3 DIPROPYLXANTHINE; ADENOSINE A2A RECEPTOR ANTAGONIST; BENZATROPINE; HALOPERIDOL; PROFENAMINE; THEOPHYLLINE; UNCLASSIFIED DRUG; ZM 241395;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CATALEPSY; CONTROLLED STUDY; DISEASE COURSE; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG MEGADOSE; DRUG POTENTIATION; EXTRAPYRAMIDAL SYNDROME; LOW DRUG DOSE; MALE; NONHUMAN; OUTCOME ASSESSMENT; RAT;

EID: 78649520556     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2010.08.003     Document Type: Article

References (45)

1. Adams M.R., Brandon E.P., Chartoff E.H., Idzerda R.L., Dorsa D.M., McKnight G.S. Loss of haloperidol induced gene expression and catalepsy in protein kinase A-deficient mice. Proc Natl Acad Sci USA 1997, 94:12157-12161.
2. Bernard V., Normand E., Bloch B. Phenotypical characterization of the rat striatal neurons expressing muscarinic receptor genes. J Neurosci 1992, 12:3591-3600.
3. Betz A.J., McLaughlin P.J., Burgos M., Weber S.M., Salamone J.D. The muscarinic receptor antagonist tropicamide suppresses tremulous jaw movements in a rodent model of parkinsonian tremor: possible role of M4 receptors. Psychopharmacology 2007, 194:347-359.
4. 2A antagonist KW 6002 (istradefylline) on pimozide-induced oral tremor and striatal c-Fos expression: comparisons with the muscarinic antagonist tropicamide. Neuroscience 2009, 163:97-108.
5. Bishnoi M., Chopra K., Kulkarni S.K. Theophylline, adenosine receptor antagonist prevents behavioral, biochemical and neurochemical changes associated with an animal model of tardive dyskinesia. Pharmacol Rep 2007, 59:181-191.
6. Bolden C., Cusack B., Richelson E. Antagonism by antimuscarinic and neuroleptic compounds at the five cloned human muscarinic cholinergic receptors expressed in Chinese hamster ovary cells. J Pharmacol Exp Ther 1992, 260:576-580.
7. 3 receptor knock-out mice. Eur J Pharmacol 2000, 391:63-73.
8. Bryant C.A., Farmer A., Tiplady B., Keating J., Sherwood R., Swift C.G., et al. Psychomotor performance: investigating the dose-response relationship for caffeine and theophylline in elderly volunteers. Eur J Clin Pharmacol 1998, 54:309-313.
9. Casas M., Ferre S., Guix T., Jane F. Theophylline reverses haloperidol-induced catalepsy in the rat. Possible relevance to the pharmacological treatment of psychosis. Biol Psychiatry 1988, 24:642-648.
10. Casas M., Torrens M., Duro P., Pinet C., Alvarez E., Udina C. Utilisation des méthilxanthines, caféine et théophylline dans le traitement des troubles extrapyramidaux secondaires aux traitements par les neuroleptiques. Encephale 1989, 15:177-180.
11. Casas M., Prat G., Robledo P., Barbanoj M., Kulisevsky J., Jané F. Scopolamine prevents tolerance to the effects of caffeine on rotational behavior in 6-hydroxydopamine-denervated rats. Eur J Pharmacol 1999, 366:1-11.
12. Chouinard G., Annable L., Ross-Chouinard A., Kropsky M.L. Ethopropazine and benztropine in neuroleptic-induced parkinsonism. J Clin Psychiatry 1979, 40:147-152.
13. 2 dopamine receptor subtypes. J Pharmacol Exp Ther 1996, 277:775-783.
14. Ferré S. An update on the mechanisms of the psychostimulant effects of caffeine. J Neurochem 2008, 105:1067-1079.
15. 2A receptors. Eur J Pharmacol 1999, 380:197-202.
16. Gjerden P., Bramness J.G., Slørdal L. The use and potential abuse of anticholinergic antiparkinson drugs in Norway: a pharmacoepidemiological study. Br J Clin Pharmacol 2009, 67:228-233.
17. Hansen T.E., Casey D.E., Hoffman W.F. Neuroleptic intolerance. Schizophr Bull 1997, 23:567-582.
18. Hauber W., Münkle M. The adenosine receptor antagonist theophylline induces a monoamine-dependent increase of the anticataleptic effects of NMDA receptor antagonists. Naunyn Schmiedebergs Arch Pharmacol 1996, 354:179-186.
19. Hoffman D.C., Donovan H. Catalepsy as a rodent model for detecting antipsychotic drugs with estrapyramidal side effect liability. Psychopharmacology 1995, 120:128-133.
20. Janno S., Holi M., Tuisku K., Wahlbeck K. Prevalence of neuroleptic-induced movement disorders in chronic schizophrenia inpatients. Am J Psychiatry 2004, 161:160-163.
21. Karasawa H., Taketo M.M., Matsui M. Loss of anti-cataleptic effect of scopolamine in mice lacking muscarinic acetylcholine receptor subtype 4. Eur J Pharmacol 2003, 468:15-19.
22. Katayama S., Ishizaki F., Yamamura Y., Khoriyama T., Kito S. Effects of anticholinergic antiparkinsonian drugs on binding of muscarinic receptor subtypes in rat brain. Res Commun Chem Pathol Pharmacol 1990, 69:261-270.
23. Keepers G.A., Casey D.E. Clinical management of acute neuroleptic-induced extrapyramidal syndromes. Curr Psychiatr Ther 1986, 23:139-157.
24. Klemm W.R. Evidence for a cholinergic role in haloperidol-induced catalepsy. Psychopharmacology 1985, 85:139-142.
25. 2a receptor-mediated modulation of striatal acetylcholine release in vivo. J Neurochem 1996, 66:1882-1888.
26. Kurz M., Hummer M., Oberbauer H., Fleischhacker W.W. Extrapyramidal side effects of clozapine and haloperidol. Psychopharmacology 1995, 118:52-56.
27. Levey A.I., Edmunds S.M., Heilman C.J., Desmond T.J., Frey K.A. Localization of muscarinic m3 receptor protein and M3 receptor binding in rat brain. Neuroscience 1994, 63:207-221.
28. Lieberman J.A. Managing anticholinergic side effects. Prim Care Companion J Clin Psychiatry 2004, 6(Suppl 2):20-23.
29. Malec D. Haloperidol-induced catalepsy is influenced by adenosine receptor antagonists. Pol J Pharmacol 1997, 49:323-327.
30. 2 receptors modulate haloperidol-induced catalepsy in rats. Eur J Pharmacol 1997, 328:135-141.
31. Miller D.D., Caroff S.N., Davis S.M., Rosenheck R.A., McEvoy J.P., Saltz B.L. Extrapyramidal side-effects of antipsychotics in a randomised trial. Br J Psychiatry 2008, 193:279-288. Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators.
32. Mintzer J., Burns A. Anticholinergic side-effects of drugs in elderly people. J R Soc Med 2000, 93:457-462.
33. Minzenberg M.J., Poole J.H., Benton C., Vinogradov S. Association of anticholinergic load with impairment of complex attention and memory in schizophrenia. Am J Psychiatry 2004, 161:116-124.
34. Moo-Puc R.E., Góngora-Alfaro J.L., Alvarez-Cervera F.J., Pineda J.C., Arankowsky-Sandoval G., Heredia-López F. Caffeine and muscarinic antagonists act in synergy to inhibit haloperidol-induced catalepsy. Neuropharmacology 2003, 45:493-503.
35. 2 receptor antagonist alters extracellular adenosine levels in the rat nucleus accumbens. Neurochem Int 2004, 44:609-615.
36. 2a receptors in rat striatum: implications for the mechanism and the treatment of tardive dyskinesia. J Neurochem 1995, 65:2057-2064.
37. Piafsky K.M., Ogilvie R.I. Dosage of theophylline in bronchial asthma. N Engl J Med 1975, 292:1218-1222.
38. Purkerson S.L., Potter L.T. Use of antimuscarinic toxins to facilitate studies of striatal m4 muscarinic receptors. J Pharmacol Exp Ther 1998, 284:707-713.
39. Richardson P.J., Dixon A.K., Lee K., Bell M.I., Cox P.J., Williams R., et al. Correlating physiology with gene expression in striatal cholinergic neurones. J Neurochem 2000, 74:839-846.
40. Saltz B.L., Robinson D.G., Woerner M.G. Recognizing and managing antipsychotic drug treatment side effects in the elderly. Prim Care Companion J Clin Psychiatry 2004, 6(Suppl 2):14-19.
41. Santiago M.P., Potter L.T. Biotinylated m4-toxin demonstrates more M4 muscarinic receptor protein on direct than indirect striatal projection neurons. Brain Res 2001, 894:12-20.
42. Stoof J.C., Drukarch B., de Boer P., Westerink B.H., Groenewegen H.J. Regulation of the activity of striatal cholinergic neurons by dopamine. Neuroscience 1992, 47:755-770.
43. 2A receptor antagonists on haloperidol-induced movement disorders in primates. Psychopharmacology 2008, 200:393-401.
44. 2 receptor regulation of apomorphine-induced turning in rats with unilateral striatal dopamine denervation. Psychopharmacology 1993, 111:383-388.
45. 1 adenosine antagonists enhance the anticataleptic action of trihexyphenidyl in rats. Neurosci Lett 2003, 346:1-4.